Vunakizumab, CAS 1792181-33-9

Product Description: Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95-102. 

CAS Number: 1792181-33-9

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P99335-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99335-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK